Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)

Inclusion Criteria: 1. Informed consent must be signed. 2. At least 18 years of age. 3. Histologically or cytologically confirmed non-small cell lung cancer (without EGFR, ALK mutation). 4. Have measurable and clinical stage II-IIIA with no known PD-L1 expression or PD-L1 ≤ 1%. 5. disease eligible for surgery. 6. No previous systematic therapy or radiotherapy. 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 8. At least one measurable lesion. 9. No major organ dysfunction, including liver, kidney, and cardiac function. Exclusion Criteria: 1. Patients with active autoimmune disease or history of autoimmune disease. 2. Patients have received other treatment for non-small cell lung cancer or for any other malignancy. 3. History of allergy to study drug components. 4. Pregnant or breast-feeding. 5. Any mental or psychological condition that would prevent the patient from completing the study or understanding the patient information. 6. Patients who have other malignancies. 7. History of major surgery or serious injury within the past 3 months. 8. HIV, HBV, HCV infection or active pulmonary tuberculosis. 9. Vaccination within 4 weeks prior to the start of the study. 10. Presence of underlying medical conditions that, in the investigator's judgment, could increase the risk associated with study drug administration or interfere with the assessment of toxicity and adverse events.